KLTO (Klotho Neurosciences) Additional Paid-In Capital : $13.43 Mil(As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Additional Paid-In Capital?

Klotho Neurosciences's quarterly additional paid-in capital increased from Sep. 2024 ($9.65 Mil) to Dec. 2024 ($11.75 Mil) and increased from Dec. 2024 ($11.75 Mil) to Mar. 2025 ($13.43 Mil).

Klotho Neurosciences's annual additional paid-in capital increased from Dec. 2022 ($3.54 Mil) to Dec. 2023 ($4.49 Mil) and increased from Dec. 2023 ($4.49 Mil) to Dec. 2024 ($11.75 Mil).

Klotho Neurosciences Additional Paid-In Capital Historical Data

The historical data trend for Klotho Neurosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Additional Paid-In Capital Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

3.54

4.49

11.75

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial						3.88	3.68	9.65	11.75	13.43

Klotho Neurosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Klotho Neurosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, Suite A, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.